{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.237","value":"0.52"},{"groupId":"OG001","spread":"2.408","value":"-0.04"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"152"}],"units":"Participants"}],"description":"The change from baseline of the mean score of pain severity at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 (\"No pain\", \"No interference\") to 10 (\"Pain as bad as you can imagine\", \"Highest imaginable interference\") numeric rating scale.","dispersionType":"Standard Deviation","groups":[{"description":"Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (Oral): On weeks without Elotuzumab dosing: Tablets, Oral, 40mg Repeat every 28 days until participants met criteria for discontinuation of study drug On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg Repeat every 28 days until participants met criteria for discontinuation of study drug Dexamethasone (IV): On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly Repeat every 28 days until participants met criteria for discontinuation of study drug Elotuzumab (BMS-901608; HuLuc63): Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\\&2); Days 1 and 15 (cycles 3 and beyond) Repeat every 28 days until participants met criteria for discontinuation of study drug","id":"OG000","title":"Lenalidomide + Dexamethasone + Elotuzumab"},{"description":"Lenalidomide: Capsules, Oral, 25 mg, once daily, on Days 1-21 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug Dexamethasone: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22 Regimen repeated every 28 days until participants met criteria for discontinuation of study drug","id":"OG001","title":"Lenalidomide + Dexamethasone"}],"paramType":"MEAN","populationDescription":"All randomized participants with baseline and end of treatment scores","reportingStatus":"POSTED","timeFrame":"From baseline up to approximately 38 months","title":"Change From Baseline of Mean Score Pain Severity (BPI-SF)","type":"SECONDARY","unitOfMeasure":"Score on a scale"}